Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Short-term Investments (2020 - 2025)

Foghorn Therapeutics has reported Short-term Investments over the past 3 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Short-term Investments at $1.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $1.2 million (changed N/A YoY), and the annual figure for FY2025 was $1.2 million, changed.
  • Short-term Investments for Q4 2025 was $1.2 million at Foghorn Therapeutics, roughly flat from $1.2 million in the prior quarter.
  • Over the last five years, Short-term Investments for FHTX hit a ceiling of $1.2 million in Q2 2025 and a floor of $25000.0 in Q3 2022.